Opening the white boxes: The licensing documentation of efficacy and safety of psychotropic medicines for children

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 5, 2009, Pages 401-411

  Aagaard, Lise ^a,b,c   Thirstrup, Steffen ^b   Hansen, Ebba Holme ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANISH MEDICINES AGENCY   (Denmark)

^c FKL Research Centre for Quality in Medicine Use   (Denmark)

Author keywords

Children; Citalopram; Denmark; Efficacy; Licensing files; Methylphenidate; Safety

Indexed keywords

CITALOPRAM; METHYLPHENIDATE; PSYCHOTROPIC AGENT;

ARTICLE; CHILD CARE; CLINICAL RESEARCH; DENMARK; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; LICENSING; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER; CHILD; DRUG CONTROL; HUMAN; INFANT; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; CITALOPRAM; DRUG AND NARCOTIC CONTROL; HUMANS; INFANT; INFANT, NEWBORN; LICENSURE; METHYLPHENIDATE; PSYCHOTROPIC DRUGS;

EID: 67649410690     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1735     Document Type: Article

References (42)

1. Keinonen T, Miettinen P, Saano V, Ylitalo P. Clinical trials in children and healthy volunteers. Quality and characteristics of notifications reviewed by the regulatory agencies in Finland. Paediatr Perinat Drug Ther 2003; 5: 175-182.
2. WHO. Promotion Safety of Medicines For Children. WHO Library: France, 2007.
3. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985-991.
4. Anonymous. Assuring trial safety for children. Lancet 2007; 371(9618): 1046.
5. Matza LS, Swensen AR, Flood EM, Secnik K, Leidy NK. Assessment of health-related quality of life in children: a review of conceptual, methodological, and regulatory Issues. Value in Health 2004; 7: 79-7992.
6. Regulation EC No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.
7. FDA Modernization Act of 1997. Available at www.fda.gov/cdrh/modact/ modguid.html Accessed April 7, 2008.
8. Sammons HM, Choorara I. Clinical trials of medication in children, 1996-2002. Eur J Clin Pharmacol 2005; 61: 165-167.
9. Process for Handling Referrals to FDA under 21 CFR 50.54 Additional Safeguards for Children in Clinical Investigations12/22/2006. Available at www.fda.gov/cber/gdlns/childclininv.pdf Accessed April 7, 2008.
10. Mastriani KS, Williams VC, Hulsey TC, Wheless JW, Maria BL. Evidence-based versus reported epilepsy management practices. J Child Neurol 2008; 23: 507-514.
11. Garland EJ. Facing the evidence: antidepressant treatment in children and adolescents. CMAJ 2004; 170: 489-491.
12. Herxheimer A, Barbara M. Antidepressants and adverse effects in young patients: uncovering the evidence. CMAJ 2004; 170: 487-488.
13. Medstat. Available at www.medstat.dk Accessed February 12, 2008.
14. Strom BL. Pharmacoepidemiology (4th edn). John Wiley & Sons Ltd: West Sussex, 2005.
15. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003; 5: 833-841.
16. Lopez F, Silva R, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin® LA and Concerta®) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 2003; 5: 545-555.
17. Silva R, Muniz R, Pestreich LK, Bram SM, Childress A, Lopez FA. Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2005; 15: 637-654.
18. Wilens TE, Biederman J. The stimulants. Pediatr Psychopharmacol 1992; 15: 191-222.
19. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999; 38: 503-512.
20. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409-432.
21. Klein RG, Mannuzza S. Long-term outcome of hyperactive children: a review. J Am Acad Child Adolesc Psychiatry 1991; 30: 383-387.
22. Rodseth D, Jayrajh J. Safety and tolerability of citalopram in children and adolescents. Poster, 2nd IFMAD meeting, Monte Carlo 2001.
23. Department of Health and Ageing, Australian Government 2006: Public Summary Document for Methylphenidate hydrochloride, extended release tablets, 18 mg, 36mg and 54 mg, Concerta® March 2006. Available at http://www.health.gov.au/ Accessed June 2, 2008.
24. Swanson JM. Comparison of the efficacy and safety of OROS methylphenidate HCL with methylphenidate three times daily and placebo in children with ADHD. Paediatr Res 2000; 47: 34A.
25. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once a day Concerta methylphenidate versus three-time-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107(6): E105.
26. Wolraich ML, Greenhill LL, Pelham W, et al. Randomised controlled trial of OROS methylphenidate once a day in children with attention deficit/hyperactivity disorder. Pediatrics 2001; 108: 883-892.
27. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CF. A randomised, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006; 13: e50-e62.
28. Stein MA, Sarampote CS,Waldman ID, et al. A dose-response study of OROS® methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 2003; 112: e404-413.
29. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004; 113: e206-e216.
30. Polanczyk G, deLima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164: 942-948.
31. Guideline on clinical investigation of medicinal products for the treatment of obsessive compulsive disorder. CHMP/EWP/4279/02 London, 20 January 2005. Available at http://www.emea.europa.eu/pdfs/human/ewp/ 427902en.pdf Accessed January 26, 2008.
32. Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-deficit/ hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 2008; 12: 217-233.
33. Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008; 18: 157-178.
34. Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry 1999; 44: 811-813.
35. Klein DF. The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology 2006; 31: 689-699.
36. Committee for Medicinal Products for Human Use July 2007 Plenary Meeting Monthly report EMEA/318931/2007. Available at http://www.emea.europa.eu/ pdfs/human/press/pr/31893107en.pdf
37. Press Release: Meeting highlights from the Committee for Medicinal Products for Human Use, Ref. EMEA/431407/2007 London, 19 July 2007.
38. Hansen EH, Launsø L. Clinical trials: towards a different model. J Pharm Clin 1987; 6: 67-74.
39. Hansen EH. Technology assessment of pharmaceuticals - the necessity of user perspective. Cah Sociol Demogr Med 1990; 30: 313-327.
40. Hansen EH. Technology assessment in a user perspective - experiences with drug technology. Int J Technol Assess Health Care 1992; 8: 150-165.
41. Aagaard L, Soendergaard B, Kampmann JP, Hansen EH. Creating knowledge about adverse drug reactions: a critical analysis of the Danish reporting system from 1968 to 2005. Soc Sci Med 2007; 65: 1296-1309.
42. Aagaard L, Soendergaad B, Stenver DI, Hansen EH. Knowledge creation about ADRs - turning the perspective from the rear view mirror to the projector? Br J Clin Pharmacol 2007; 65: 364-376.